Alto Neuroscience Inc. (NYSE: ANRO) is a California-based biopharmaceutical company developing personalised treatments for mental health conditions. It focuses on innovative therapies for major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and schizophrenia, with promising drug candidates like ALTO-100 and ALTO-300. The company is also pioneering a biomarker-based platform to tailor treatments, using patient-specific biological data to improve outcomes. Since its founding in 2019, Alto Neuroscience has been at the forefront of personalised mental health care.
The Q1 2025 earnings season for the Magnificent Seven—Apple, Microsoft, Nvidia, Amazon, Alphabet, Meta Platforms, and Tesla—revealed a shared strategic emphasis on artificial intelligence, infrastructure investment, supply chain resilience, and capital discipline.
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.